Anniversaries

The Independent - London | February 15, 1994 | Copyright

Births: Sigismund, Holy Roman Emperor and King of Hungary, 1368; Philipp Melanchthon (Schwarzerd), reformer and theologian, 1497; Pedro Menendez de Aviles, navigator, 1519; Galileo Galilei, astronomer and mathematician, 1564; Michael Praetorius (Schultheiss), composer and musical historian, 1571; Matthew Merian the Younger, engraver and painter, 1687; Charles Andrew Vanloo, painter, 1705; Louis XV, King of France, 1710; Jean- Nicolas Buache, geographer and cartographer, 1741; Jeremy Bentham, philosopher and writer, 1748; Friedrich Ernst Fesca, violinist and composer, 1789; Cyrus Hall ...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and trade journal articles from HighBeam Research

(Including press releases, facts, information, and biographies)

Rigel Pharmaceuticals' Stockholders Approve Financing and Other Related Proposals at Annual Stockholders' Meeting.
PR Newswire ; Rigel Pharmaceuticals, Inc. announced today that it received...submitted for stockholder vote and identified in Rigel's 2003 proxy statement. Among the proposals receiving approval were Rigel's recently announced financing, a reverse stock...
Rigel Announces Third Quarter 2008 Financial Results and Clinical Update.
PR Newswire ; ...Nov. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today reported...2008. For the third quarter of 2008, Rigel reported a net loss of $37.7 million...in the third quarters of 2008 and 2007. Rigel reported operating expenses of $38.7...
Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity.
PR Newswire ; Rigel Program to be Presented at Keystone Scientific...March 27 /PRNewswire-FirstCall/ -- Rigel today announced that Yonchu Jenkins, Ph...Function. Dr. Jenkins and her colleagues at Rigel are investigating ways to inhibit Vif, a...
Rigel Announces 2002 Fiscal Year Financial Results; Company Provides Outlook for 2003 Clinical Progress.
PR Newswire ; ...Calif., Feb. 5 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. today reported...with the start of clinical testing for Rigel's first product candidate. Net loss...fiscal 2001. As of December 31, 2002, Rigel had cash, cash equivalents and short...
Rigel Granted Key Patents in Immunology, Virology and Oncology.
PR Newswire ; ...March 21 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced...patents since February 2004. Specifically, Rigel was granted six patents in immunology...Activated Cell Sorter (FACS) technology. Rigel is ranked as one of the top 15 biotech...
Rigel Pharmaceuticals Presents Drug Development Programs in Oncology and Allergy/Inflammation at the Protein Phosphorylation Drug Discovery World Summit; Presentations to Feature Latest Results on Inhibitors of Ubiquitin Ligases and Selected Kinases as Potential Drug Candidates.
PR Newswire ; Rigel Pharmaceuticals, Inc., announced today...for the treatment of cancer. Another of Rigel's programs focuses on a kinase drug target...arthritis," said Donald G. Payan, M.D., Rigel's executive vice president and chief scientific...
Rigel Announces Restructuring To Reduce Spending; Company Cuts Staff While Increasing Focus on Major Drug Development Programs.
PR Newswire ; Rigel Pharmaceuticals announced today that the...As a result of this reduction in force, Rigel will realign its personnel base, predominantly...company's drug development capabilities. Rigel also announced today that, separately from...
Rigel Announces Fourth Quarter and Year End 2007 Financial Results.
PR Newswire ; ...Feb. 12 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced...2007. For the fourth quarter of 2007, Rigel reported a net loss of $19.0 million...million and 25.1 million, respectively. Rigel reported revenue from collaborations of...
Rigel Secures Hepatitis C Virus License Agreement From Chiron Corporation.
PR Newswire ; Rigel Pharmaceuticals, Inc. today announced that...agreement with Chiron Corporation granting Rigel a license to discover, develop and commercialize...disclosed. "Today's agreement provides Rigel with the flexibility to pursue our innovative...
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP.
PR Newswire ; ...Nov. 21 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced...T. Participating on the call will be Rigel senior management and the principal investigator...Cornell Medical College. In addition, Rigel will be presenting a poster on R788 in...

Find more facts and information related to the article "Anniversaries"